tbuckley/cabot-search huggingface dataset:
Hemorrhagic Colitis Associated with a Rare<i>Escherichia coli</i>Serotype
Authors: Lee W. Riley, Robert S. Remis, Steven D. Helgerson, Harry B. McGee, Joy G. Wells, Betty R. Davis, Richard J. Hebert, Ellen S. Olcott, Linda M. Johnson, Nancy T. Hargrett, Paul A. Blake, Mitchell L. Cohen
Journal: New England Journal of Medicine (1983)

We investigated two outbreaks of an unusual gastrointestinal illness that affected at least 47 people in Oregon and Michigan in February through March and May through June 1982. The illness was characterized by severe crampy abdominal pain, initially watery diarrhea followed by grossly bloody diarrhea, and little or no fever. It was associated with eating at restaurants belonging to the same fast-food restaurant chain in Oregon (P less than 0.005) and Michigan (P = 0.0005) and with eating any of three sandwiches containing three ingredients in common (beef patty, rehydrated onions, and pickles). Stool cultures did not yield previously recognized pathogens. However, a rare Escherichia coli serotype, O157:H7, that was not invasive or toxigenic by standard tests was isolated from 9 of 12 stools collected within four days of onset of illness in both outbreaks combined, and from a beef patty from a suspected lot of meat in Michigan. The only known previous isolation of this serotype was from a sporadic case of hemorrhagic colitis in 1975. This report describes a clinically distinctive gastrointestinal illness associated with E. coli O157:H7, apparently transmitted by undercooked meat.
A Prospective Study of Obesity and Risk of Coronary Heart Disease in Women
Authors: JoAnn E. Manson, Graham A. Colditz, Meir J. Stampfer, Walter C. Willett, Bernard Rosner, Richard R. Monson, Frank E. Speizer, Charles H. Hennekens
Journal: New England Journal of Medicine (1990)

We examined the incidence of nonfatal and fatal coronary heart disease in relation to obesity in a prospective cohort study of 115,886 U.S. women who were 30 to 55 years of age in 1976 and free of diagnosed coronary disease, stroke, and cancer. During eight years of follow-up (775,430 person-years), we identified 605 first coronary events, including 306 nonfatal myocardial infarctions, 83 deaths due to coronary heart disease, and 216 cases of confirmed angina pectoris.
PET/CT Imaging of Abdominal Aorta With Intramural Hematomas, Penetrating Ulcer, and Saccular Pseudoaneurysm
Authors: Vien X. Nguyen, Ba D. Nguyen
Journal: Clinical Nuclear Medicine (2013)

Acute aortic syndromes, encompassing intramural hematoma, penetrating ulcer, and pseudoaneurysm, are best demonstrated by angiographic CT and magnetic resonance imaging. These imaging modalities provide an accurate evaluation and allow timely therapies of these frequently symptomatic lesions, thus reducing their morbidity and mortality. The inflammatory pathogenesis of these acute aortic syndromes may exhibit positive PET findings predictive of prognosis and outcomes of these vascular events. The authors present a case of PET/CT imaging showing asymptomatic intramural hematomas with penetrating ulcer and saccular pseudoaneurysm of the proximal abdominal aorta.
AB0016 Association between the hla-b51 antigen and profiles of peripheral t cell subsets in tunisian patients with behcet’s disease
Authors: K. Sakly, C. Lambert, M. Maatouk, S. Hammami, N. Sakly, O. Harzallah, S. Mahjoub, I. Ghedira, S. Feki
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Behçet's disease (BD) is a multisystemic inflammatory disorder characterized by spontaneous remissions and relapses [1]. An association between Behçet's disease and HLA-B51 has been regarded as the strongest evidence for involvement of genetic factors in its pathogenesis. The exact mechanisms illustrating the involvement of HLA-B51 in BD development are still unknown [2]. <h3>Objectives</h3> The aim of this study was to assess possible associations between the expression of HLA-B51 antigen and particular profiles of peripheral T cell subsets in patients with BD. <h3>Methods</h3> 30 patients with BD, 19 males and 11 females (mean age: 39.65±10.7 years) were enrolled in this study. Ten of them had active disease. The following monoclonal antibody combination was used to characterize the phenotypes of T cells: anti-CD4-Chrome orange/anti-CD3-PacificBlue/anti-CD62L-PE/anti-CD127-APC-Cy7/anti-CD25-PerCP-Cy5/anti-CD45RA-PCy7 and anti-CD8-APC. Analysis was performed on a FACSDiva™ flow cytometer using FACSDiva™ software. The HLA-B51 typing was performed using the complement dependent microlymphocytotoxicity technique. <h3>Results</h3> Our study showed that 38.46 % of patients with BD were HLA-B51 positive (positive group). This group, as compared with HLA-B51 negative patients (negative group), tend to have fewer CD45RA+CD62L+CD4+ naïve T cells (6.77 ± 4.7% versus 8.18 ± 6.5%, p=0.9 ) and higher CD45RA-CD62L+CD4+ central memory T cells (22.7 ± 13.6% versus 13.18 ± 12.2%, p=0.2). The HLA-B51 positive group showed also lesser terminally differentiated CD45RA+CD62L–CD4+ effector memory T cells than the negative group (8.18±3.1% versus 16.86 ± 5%; P = 0.018). However, regarding CD45RA–CD62L–CD4+ effector memory T cells and CD4+CD25brightCD127- T reg cells, no differences were found between the two groups. Moreover, the HLA-B51 positive group seems to be characterized by decreased percentage of CD45RA+CD62L+CD8+ naïve T cells compared to negative group (8.11±3.7% versus 14.02±6.7%; P=0.08). Finally, no differences were found between the two groups regarding CD45RA-CD62L+CD8+ central memory T cells, CD45RA–CD62L–CD8+ effector memory T cells and terminally differentiated CD45RA+CD62L– CD8+ effector memory T cells. <h3>Conclusions</h3> Our study showed that HLA-B51 positive patients with BD are characterized by particular profiles of T cells. The understanding of these findings could contribute in elucidating the role of HLA-B51 antigen expression in the pathogenesis of BD. <h3>References</h3> Kaneko, F., et al., Behcet's disease (Adamantiades-Behcet's disease). Clin Dev Immunol, 2011. 2011: p. 681956. <h3>Disclosure of Interest</h3> None Declared
THU0379 Efficacy and Safety of Anti-TNF Alpha in NON Infectious Inflammatory Uveitis: Preliminary Results of A French Multicenter Registry of 162 Patients
Authors: H. Vallet, P. Seve, S. Riviere, L. Perard, P. Bielefeld, S. Abad, A. Rigolet, A. Perlat, O. Fain, B. Bienvenu, T. Le Hoang, D. Sene, N. Tieulie, B. Wechsler, C. Chapelon, J.B. Fraison, Y. Schoindre, B. Bodaghi, P. Cacoub, D. Saadoun
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Etiologies of non infectious inflammatory uveitis are multiple. Their prognosis can be severe and may lead to blindness. Anti-TNF alpha are used for several years in refractory inflammatory uveitis but few data on large studies have been reported. <h3>Objectives</h3> The aim of this study is to report on the efficacy and the safety of anti-TNF alpha in inflammatory uveitis. <h3>Methods</h3> We performed a retrospective multicenter study of main characteristics and outcomes of 162 patients with inflammatory uveitis treated with anti-TNF alpha. <h3>Results</h3> The median of age was 30 years [19-40] and with 59% of women. Uveitis were mainly bilateral (82%) and chronic (87%). Panuveitis, macular oedema and retinal vasculitis were observed in 62, 54 and 35% of cases, respectively. Main etiologies of uveitis included juvenile idiopathic arthritis (25%), Behçet9s disease (24%), spondylarthropathies (12%), and sarcoidosis (6%). Patients were treated by infliximab in 58%, adalimumab in 39.5% or etanercept in 2.5%. The median of follow up was 27 months [8-55]. Ninety three percent of patients were complete or partial responders to anti-TNF alpha therapy. No significant difference was found relative to efficacy between infliximab and adalimumab. Anti-TNF alpha had a significant corticosteroid sparing effect (daily prednisolone dose of 20mg at time of introduction of anti-TNF alpha vs 10mg and 5mg at 6 and 12 months, respectively; p&lt;0,0001). The median time for clinical improvement was 67 days [43-103]. Adverse events were reported in 27% of patients, mainly with infliximab. They included mainly infections (8%) and hypersensitivity reactions (7%). Serious side effects were reported in 10% of cases and required treatment interruption in all cases. <h3>Conclusions</h3> These preliminary results showed that TNF alpha inhibitors are highly efficient in severe and refractory non infectious inflammatory uveitis. Infliximab and adalimumab had the same efficacy profile but infliximab was associated with more frequent and more serious side effects. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6013
It's Not All in Your Head
Authors: Kathryn Towns, Paul E. Szmitko, Chris Smith, Allan S. Detsky, Ophyr Mourad
Journal: New England Journal of Medicine (2011)

A 63-year-old man presented to the emergency department with shaking chills and drenching sweats of 4 days' duration. He reported no weight loss, arthralgias, headache, visual changes, or new skin eruptions, but he had progressively worsening bilateral anterior thigh pain of 10 days' duration.
Case 34-2000
Authors: Joseph R. Madsen, Diane Karluk
Journal: New England Journal of Medicine (2000)

Presentation of CaseA 71-year-old woman was admitted to the hospital because of a pituitary mass.During the five years before admission, the patient had been tired and anorectic, her joints had ached, and her neck and shoulders had become stiff. A diagnosis of polymyalgia rheumatica had been made, and she had refused to take prednisone. She had become depressed after the death of her husband 12 years before admission. Because she frequently traveled within the United States to visit her daughters, her medical care was fragmented and inconsistent. Laboratory tests performed six years before admission showed hyperlipidemia, with normal . . .
P397What are the specific features of Fabry cardiomyopathy?
Authors: S El Ghannudi, A Lefoulon, E Neol, P Germain, S Doutreleau, MI-Y Jeung, A Gangi, A Roy
Journal: Cardiovascular Research (2014)

Aim: To determine specific clinical, ECG, echocardiography and cardiac magnetic resonance imaging (CMR) features of fabry disease cardiomyopathy (FCM) in comparison to FD patients without cardiac involvement (N-FCM). Methods: We retrospectively included sixty height subjects, thirty-four patients with FD and thirty-four normal (N) subjects between 2004 and 2013. Detailed demographic, clinical, any organ involvement, ECG, echocardiography and CMR features were recorded. In this study FCM was considered present in subjects with left ventricular hypertrophy based on echocardiography measurement and or the presence of at least two of the following criteria : inverted T waves, Sa velocity at lateral mitral annulus <8 m/sec, global longitudinal strain <18%. Results: The age was 39 [31.5-54.5] years. No difference in demography of the groups. Higher ECG conduction abnormalities (44.1% vs 14.7%, p=0.02), shorter PR (20.6% vs 0%, p=0.01), and higher frequency of inverted T waves (29.4 % vs 0%, p<0.001) in FD vs N. Higher left ventricular mass (LVM) (187.8 [165.9-213] vs 131 [106.1-158], p<0.001), diastolic left ventricular diameter (98 [82-110] vs 75.5 [70-81], p=0.006) and E/Ea (6 [6-7.9] vs 6 [5-6.1], p=0.02), cardiac index (3.25 [2.5-4.4] vs 2.72 [2.4-2.9], p = 0.01), left atrium diameter (19 [17.6-21] vs 15 [13.8-18], p<0.001), diastolic right ventricular diameter (9.4 [7.9-10.2] vs 8.1 [7.2-8.8], p= 0.02) in FD vs N group. In FD, there was (70.1%) cardiac (FCM), (55.9%) renal, (61.8%) neurological, (64.7%) dermatological, (76.5%) ORL, (82.4%) ophthalmologic, (11.8%), pulmonary involvements. 79.4% was under treatment, duration treatment was 35.2 [9-81] months. No difference regards treatment between FCM and N-FCM. No difference in cardiovascular clinical symptoms between FCM and N-FCM. No difference in all organs involvements between FCM and N-FCM. No difference in ECG features except for inverted T waves (FCM 5 (20.8%) vs (0%) in N-FCM, p= 0.02). Higher echocardiography LVMI (117 [97.7-126.8] vs 86 [65-98], p<0.001), a lower E wave velocity in FCM as compared to N-FCM (79 [66.3-92] vs 99 [85.4-105], p= 0.02). In FCM, the LVMI was correlated with age (r=0.6, p=0.0015), and inversely correlated to E/A (r=-0.5, p=0.019). In contrast, LVMI was not correlated to inverted T waves on ECG (r=0.17, p=0.41). Using, cardiac MRI myocardial fibrosis was present in 4 (16.6%) in FCM. Conclusion: The diagnosis of early stage FCM is still challenging. There are no specific clinical features of FCM. The inverted T waves could be useful in the diagnosis of early stage of FCM even without the presence of LVH.
Indium-111 Leukocyte Scintigraphy Aids in Diagnosis of Tubo-Ovarian Abscess
Authors: Medina C. Kushen, Hung Q. Dam, Timothy A. Manzone
Journal: Clinical Nuclear Medicine (2011)

Indium-111 leukocyte scintigraphy is used widely in the setting of fever of unknown origin. This modality has variable reported ranges of sensitivity and specificity; however, it is a useful technique in establishing the cause of fever of unknown origin. We describe a case of 47-year-old woman who presented with fever and leukocytosis and was subsequently found to have tubo-ovarian abscess detected by Indium-111 leukocyte scintigraphy. The anatomic imaging in this case was nonspecific. We conclude that Indium-111 leukocyte scintigraphy is useful in diagnosis of tubo-ovarian abscess, and positive findings warranted surgical exploration in this patient.
Abstract 4276: Characterization of an ex vivo primary multicellular renal cell culture as a potential model system for renal cell carcinoma tumorigenesis
Authors: Alexandra Arreola, W. Kimryn Rathmell
Journal: Cancer Research (2011)

Abstract Sporadic and germline mutations or loss of the von Hippel-Lindau (VHL) tumor suppressor gene have been linked to varying levels of risk for Renal Cell Carcinoma (RCC). RCC is a highly prevalent malignancy that affects roughly 56,000 people annually in the United States. With no true murine model for RCC, patient derived renal carcinoma cell lines and mouse embryonic stem cell lines have been largely used for the study of this malignancy. The purpose of this study is to generate an ex vivo model for Renal Cell Carcinoma using primary neonatal epithelial kidney cells grown as multicellular cultures. To better understand the genetic changes associated with RCC tumor formation following VHL loss or inactivation, primary epithelial kidney cells from newborn conditional Vhl null and Vhl G518A mutant genetically engineered mouse lines are undergoing investigation. Analysis of primary neonatal epithelial kidney cells cultured under mild hypoxia show that these cells preferentially grow in an organized multicellular spherical culture. Additionally, these multicellular cultures, termed “renospheres”, display focal expression of progenitor cell marker CD133, and also globally express Oct4 while select cells in the renospheres express renal cell type markers as seen by immunohistochemistry. Current work is aimed at identifying the cellular makeup of these spheres and determining any role individual cellular components may have in tumorigenesis. Future plans will compare growth characteristics and cellular components of renospheres in the setting of VHL mutation or loss with those with an intact VHL network. This ex vivo system can provide insight into both the cellular characteristics and molecular events that contribute substantially to RCC tumor formation as growth conditions of the renospheres are meant to mimic as close to a physiological state as possible, a factor not currently being addressed by common practices in the field. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4276. doi:10.1158/1538-7445.AM2011-4276
815 FACTORS ASSOCIATED WITH INTOLERANCE TO PEGINTERFERON alfa/RIBAVIRIN IN TREATMENT-NAÏVE, CIRRHOTIC/NON-CIRRHOTIC HCV GENOTYPE 1-INFECTED PATIENTS: ANALYSIS OF DATA FROM THE MULTINATIONAL PROPHESYS COHORTS
Authors: R. Firpi, N. Reau, E. Korner, R. Hoop, J. Han, A. Mangia, P. Ferenci, G. Everson
Journal: Journal of Hepatology (2013)
THU0256 Does Socioeconomic Status Affect Outcomes in Early Rheumatoid Arthritis? Data from A Multi-Site Canadian Inception Cohort: Table 1
Authors: G. Yang, V. Bykerk, B.P. Haraoui, C. Thorne, D. Tin, C. Hitchon, G. Boire, E. Keystone, J.E. Pope
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Socioeconomic status (SES) may affect outcomes in a chronic disease due to health related behaviors and/or access to healthcare including physician visits and medications. Early rheumatoid arthritis outcomes may be affected in a country with universal healthcare (for physician visits) but not medications. <h3>Objectives</h3> To assess the impact of socioeconomic status (SES) on outcomes in patients with early inflammatory arthritis using data from the Canadian Early Arthritis Cohort (CATCH) study. <h3>Methods</h3> The CATCH cohort recruited 2023 patients prospectively with early RA (confirmed or suspected), and allocated to low- or high-SES groups based on education and income. Outcomes at baseline and 12 months were analyzed in relation to SES including the Disease Activity Score (DAS28), Simplified Disease Activity Index (SDAI), pain, patient global assessment scale (PTGA), the Health Assessment Questionnaire Disability Index (HAQ), and the SF12-v2 Health Survey, using the analysis of variance (ANOVA), Chi-squared test and regression analyses. <h3>Results</h3> The CATCH patients had 43% with high school education or less and 37% in the low-income group (&lt;$50,000 Canadian per annum household income). The low-education group had higher DAS28 (p=0.045) at baseline becoming non-significant at 12 months. Patients in the low-income group presented with higher HAQ (p=0.017), pain (p=0.035), PTGA (p=0.004), and SDAI (p=0.022). Low-income vs. high-income groups were associated with an odds ratio (OR) above the median for: HAQ 1.20 (95% CI 1.00-1.45), PTGA 1.27 (95% CI 1.06-1.53), and SDAI 1.25 (95% CI 1.02-1.52) at baseline. The predictive value of low income for HAQ persisted at 12 months, OR 1.30 (95% CI 1.02-1.67) but not for other variables. Characteristics of the CATCH patients (0.001<sup>#</sup> is P&lt;0.001). <h3>Conclusions</h3> Low SES is associated with higher disease activity, poorer physical function, more pain, higher PTGA, and higher HAQ at baseline. HAQ remains worse at one-year follow-up in this population. <h3>Disclosure of Interest</h3> : G. Yang: None declared, V. Bykerk: None declared, B. Haraoui: None declared, C. Thorne: None declared, D. Tin: None declared, C. Hitchon: None declared, G. Boire: None declared, E. Keystone: None declared, J. Pope Grant/research support: The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. via an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium (UCB) Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Laboratories Ltd., and Janssen Biotech Inc. <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2737
P162 Effect of adding propranolol or increased inhaled corticosteroid dose in persistent asthma
Authors: WJ Anderson, PM Short, PA Williamson, A Manoharan, BJ Lipworth
Journal: Thorax (2013)

<h3>Introduction and Objectives</h3> Chronic propranolol does not improve airway hyper-responsiveness (AHR) in persistent asthmatics taking medium dose inhaled corticosteroid (ICS), 440µg/day<sup>1</sup>. We wished to assess for any putative corticosteroid-sparing effect of propranolol added to low dose ICS versus higher dose ICS, on histamine AHR. <h3>Methods</h3> We conducted a randomised double-blind placebo-controlled crossover trial in mild-moderate persistent asthmatics. Patients were run-in for 2 weeks on hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) 100µg/day. Patients were then randomised to either: propranolol 80mg/day plus HFA-BDP 100µg/day; or placebo plus HFA-BDP 400µg/day, each for 4 weeks. Propranolol was up-titrated to 80mg/day for the second 2 weeks of treatment. Patients received tiotropium 18µg/day during run-in and both treatments, which was subsequently discontinued 5 days prior to histamine challenge (primary outcome). <h3>Results</h3> 16 patients completed, mean: age 38yr; FEV<sub>1</sub> 86.4%; Histamine PC<sub>20</sub> 1.39mg/ml; ICS 406µg/day. Histamine PC<sub>20</sub> remained unchanged adding propranolol to HFA-BDP100 compared to baseline (HFA-BDP100): 0.17 doubling dilution (dd) difference (95%CI -0.58–0.92), but there was a significant improvement with HFA-BDP400 compared to both baseline 1.05dd (95%CI 0.43–1.66), P = 0.02; and propranolol 0.88dd (95%CI 0.45–1.30), P = 0.006 (Figure 1a). Significant improvements from baseline were observed with HFA-BDP400 for exhaled nitric oxide, blood eosinophils (Figure 1b) and Asthma Quality of Life Questionnaire (AQLQ) symptom score (Figure 1c), but not with propranolol. Salbutamol recovery time post-challenge was partially blunted by propranolol (median prolongation 5min compared to both baseline and HFA-BDP400, P = 0.002). Domiciliary evening FEV<sub>1</sub> also fell with propranolol (mean reduction from baseline 0.22L [95%CI 0.10–0.34L], P = 0.012) while Asthma Control Questionnaire (ACQ) showed no significant changes with either treatment compared to baseline. <h3>Conclusions</h3> In mild-moderate persistent asthmatics, propranolol produced no additive effects on top of low dose ICS, while further significant improvements in AHR and inflammation were seen with a higher dose of ICS. Propranolol attenuated salbutamol recovery and reduced evening FEV<sub>1</sub>, but not ACQ or AQLQ. <h3>References</h3> Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomised placebo- controlled trial to evaluate chronic dosing effects of propranolol in asthma. <i>Am J Respir Crit Care Med</i> 2013;187:1308–1314.
L'endomicroscopie confocale par minisondes permet de mieux caractériser les sténoses biliaires indéterminées: une étude rétrospective
Authors: F Caillol, B Filoche, M Gaidhane, M Kahaleh
Journal: Endoscopy (2012)

Le diagnostique histologique des sténoses biliaires est difficile avec un rendement diagnostique de 50% en utilisant les biopsies et brossages endo-canalaires. L'endomicroscopie (ECM) est une technique permettant l'obtention de biopsies optiques avec un rendement de plus de 80%. But de l'étude: Evaluation rétrospective de la précision diagnostique de l'ECM pour la caractérisation des sténoses indéterminées des voies biliaires et affinement des critères d'interprétation (critères de Miami).